ID: ALA3799932

Max Phase: Preclinical

Molecular Formula: C25H30N6O3

Molecular Weight: 462.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)Cc1cccc(NC(=O)C2(CN)CCN(c3ncnc4[nH]c5c(c34)CCC5)CC2)c1

Standard InChI:  InChI=1S/C25H30N6O3/c1-34-20(32)13-16-4-2-5-17(12-16)29-24(33)25(14-26)8-10-31(11-9-25)23-21-18-6-3-7-19(18)30-22(21)27-15-28-23/h2,4-5,12,15H,3,6-11,13-14,26H2,1H3,(H,29,33)(H,27,28,30)

Standard InChI Key:  DSWZDIKQFDCBGM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 462.55

Molecular Weight (Monoisotopic): 462.2379

AlogP: 2.35

#Rotatable Bonds: 6

Polar Surface Area: 126.23

Molecular Species: BASE

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.68

CX Basic pKa: 9.16

CX LogP: 2.45

CX LogD: 0.68

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.48

Np Likeness Score: -0.88

References

1. Alen J, Bourin A, Boland S, Geraets J, Schroeders P, Defert O.  (2016)  Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structureactivity studies,  7  (3): [10.1039/C5MD00473J]

2. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source

Source(1):

• Scientific Literature